Search Within

Anita Kumar

Formats
  1. Meeting Abstract (112)
  2. Journal Article (64)
  3. Review (8)
  4. Book Section (6)
  5. Research Letter (5)
  6. Correspondence (1)
  7. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (197)
  2. Department of Medicine (197)
  3. Hematologic Malignancies, Division of (197)
  4. Lymphoma (197)
  5. Survivorship Research (104)
  6. Population Sciences Research Program (103)

More Groups

People
  1. Andrew Zelenetz (136)
  2. Paul Hamlin (107)
  3. Alison Moskowitz (105)
  4. Ariela Noy (105)
  5. Maria Palomba (100)
  6. Steven Horwitz (98)

More People

Years
  1. 2025 (7)
  2. 2024 (33)
  3. 2023 (32)
  4. 2022 (12)
  5. 2021 (24)
  6. 2020 (17)

More Years

Publications
  1. Blood (84)
  2. Hematological Oncology (19)
  3. Journal of Clinical Oncology (13)
  4. Blood Advances (11)
  5. Haematologica (9)
  6. Leukemia and Lymphoma (8)

More Publications

Publishers
  1. American Society of Hematology (96)
  2. Wiley Blackwell (19)
  3. American Society of Clinical Oncology (13)
  4. Nature Publishing Group (10)
  5. Ferrata Storti Foundation (9)
  6. Taylor & Francis Group (9)

More Publishers

Results (197)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Tumor determinants of response to CAR-T therapy in relapsed or refractory mantle cell lymphoma
    Meeting Abstract

    Epstein-Peterson, Z. D.; Ryan, C. E.; Devlin, S. M.; Accav, N. G.; Avigdor, A.; Corona, M.; Danylesko, I.; Dela Cruz, J.; Goy, A.; Jacobson, C. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A single-cell atlas of classical mantle cell lymphoma reveals paired tumor-immune malignant states correlating with prognosis
    Meeting Abstract

    Marouf, A.; Mitra, S.; Isgor, I.; Joseph, A.; Rahman, J.; Lin, Y. H.; Takizawa, M.; Chaligne, R.; Sethi, S.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: A multicenter analysis
    Meeting Abstract

    Epstein-Peterson, Z. D.; Lionel, A. C.; Joseph, A.; Drill, E.; Atallah-Yunes, S. A.; Brooks, T. R.; Chong, E. A.; Chong, E. R.; Dela Cruz, J.; Frank, M. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Practice patterns inform patient-centered approaches for the integration of BTK inhibitors in frontline mantle cell lymphoma
    Meeting Abstract

    Graham, T.; Ackbarali, T.; Kumar, A.; Matasar, M.
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (RR) mantle-cell lymphoma (MCL) by race/ethnicity and TP53 mutation status
    Meeting Abstract

    Phillips, T. J.; Danilov, A. V.; Ruan, J.; Patel, K.; Kumar, A.; Wang, Y. C.; Maglinte, G. A.; Seymour, E.; Kamdar, M.
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes
    Meeting Abstract

    Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Updated safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
    Correspondence

    Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save